Reducing Cancer Health Disparities in Detroit

减少底特律的癌症健康差异

• 批准号: 10289601
• 负责人: GEROLD BEPLER
• 金额: $ 99.34万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10289601
• 关键词: Address; African American; Area; Automobile Driving; Awareness; Behavioral; Biological; Cancer Biology; Cancer Burden; Cancer Patient; Censuses; Cities; Clinical; Clinical Trials; Communities; Community Outreach; Comprehensive Cancer Center; County; Development; Disease; Enrollment; Ensure; Environment; Evaluation; Face; Foundations; Funding; Future; Genetic; Genetic Diseases; Genetic Medicine; Genomics; Guidelines; Home; Household; Immune; Immune checkpoint inhibitor; Immunotherapy; Income; Individual; Institutes; Malignant Neoplasms; Malignant neoplasm of lung; Medically Underserved Area; Mentors; Michigan; Minority Groups; Modeling; Molecular Genetics; New Agents; Outcome; Participant; Patients; Population; Population Heterogeneity; Poverty; Quality of life; Race; Reporting; Research; Research Personnel; Research Project Grants; Scientist; Specialized Program of Research Excellence; Structure; Time; Translating; Translational Research; Translations; Tumor Markers; Underserved Population; United States Health Resources and Services Administration; Universities; Work; base; cancer health disparity; cancer prevention; cancer site; cancer therapy; clinical application; community engagement; disparity reduction; health disparity; high risk; immune-related adverse events; improved; innovation; member; metropolitan; novel marker; patient engagement; patient population; precision medicine; programs; racial disparity; racial diversity; recruit; response; side effect; standard care; standard of care; treatment response; tumor

Overall Program Summary This application for Feasibility and Planning Studies of a P20 Specialized Program of Research Excellence (SPORE) to Investigate Cancer Health Disparities will address racial disparities in metropolitan Detroit, a uniquely important underserved population where great cancer disparities exist. The application includes two scientific projects focused on treatment with immune checkpoint inhibitors (ICIs) now being used in the standard of care setting for lung cancer, an Administrative Core, a Biospecimen Core, a Patient and Community Engagement Core, and a Developmental Research Program. The decision to use ICIs relies heavily on prior treatment response and imperfect tumor biomarkers, and immune-related adverse events (irAEs) dictate continued therapy, and ultimately outcomes, yet little is known about what factors drive disease course in racially diverse populations. The Overall Aim 1 of this Program is to accelerate translational research to reduce health disparities in lung cancer outcomes by: a) characterizing race-specific immune profiles with respect to the tumor environment and host genetic background to determine their contribution to response to ICIs (Project 1); and b) characterizing patient-reported side effects, quality of life, and irAEs in a racially diverse group of lung cancer patients and identifying the individual, behavioral, molecular/genetic and disease-specific determinants of these end points (Project 2). The Overall Aim 2 is to strengthen the existing programmatic structure to encourage translational research into the biology of cancer health disparities, achieve full P50 SPORE funding, and ultimately reduce cancer health disparities by: a) expanding our Cancer Biology of Health Disparities initiative, facilitating use of biospecimens from KCI's racially diverse population, and funding Developmental Research Projects; b) mentoring investigators in cancer health disparities; and c) expanding our community outreach and engagement efforts through a robust Patient and Community Engagement Core (PCEC) to support recruitment and retention of diverse study participants and dissemination of research project progress and findings to participants and lay audiences. This P20 application will enable clinical, basic and population scientists to translate relevant, high-impact scientific discoveries in diverse patients to reduce racial disparities in cancer outcomes, moving towards a more race-inclusive, equity-focused precision medicine approach to cancer treatment and prevention.

总体计划摘要 该P20专业研究计划的可行性和计划研究的申请 （孢子）调查癌症健康差异将解决底特律大都会的种族差异， 存在巨大癌症差异的独特重要人群。该应用程序包括两个 科学项目专注于使用标准中使用免疫检查点抑制剂（ICI）的治疗 肺癌的护理设置，行政核心，生物循环核心，患者和社区 参与核心和发展研究计划。使用ICIS的决定严重依赖于先验 治疗反应和不完美的肿瘤生物标志物以及免疫相关的不良事件（IRAE）决定了 持续的治疗，最终的结果，但对哪些因素推动了种族疾病的疾病课程知之甚少 多样化的人群。该计划的总体目标1是加速转化研究以减少健康 肺癌结局的差异：a）表征种族特异性免疫特征相对于肿瘤 环境和宿主遗传背景，以确定其对ICIS反应的贡献（项目1）；和b） 表征患者报告的副作用，生活质量和伊拉斯在种族多样的肺癌中 患者并识别这些人，行为，分子/遗传和疾病特异性决定因素 终点（项目2）。总体目标2是加强现有的程序结构以鼓励 对癌症健康差异生物学的转化研究，实现完整的P50孢子资金以及 最终通过以下方式降低癌症健康差异：a）扩大我们的健康差异倡议的癌症生物学， 促进KCI种族多样性人群的生物测量和资助发展研究 项目； b）指导调查人员癌症健康差异； c）扩大我们的社区宣传和 通过强大的患者和社区参与核心（PCEC）的参与工作，以支持招聘 并保留各种研究参与者，并将研究项目进步和发现传播给 参与者和外行观众。该P20应用将使临床，基础和人群科学家能够 翻译不同患者的相关，高影响的科学发现，以减少癌症的种族差异 结果，朝着更具种族的，以股票为重点的精确药物的癌症迈向癌症 治疗和预防。